Shared on04 Sep 25Fair value Increased 0.32%
As key metrics including the discount rate (7.16%) and net profit margin (16.85%) remained stable, the consensus analyst price target for Medpace Holdings was unchanged at $422.27. What's in the News Medpace completed a repurchase of 1,754,264 shares (5.89% of shares outstanding) for $518.54 million in Q2 2025, bringing the total buyback under its current program to 14.76% of shares outstanding and $1.27 billion since October 2022 (Key Developments).
Shared on30 Apr 25Fair value Decreased 16%
AnalystConsensusTarget has decreased revenue growth from 6.1% to 5.1% and decreased future PE multiple from 21.6x to 18.9x.
Shared on23 Apr 25Fair value Decreased 8.03%
AnalystConsensusTarget has decreased revenue growth from 7.2% to 6.1% and decreased future PE multiple from 25.0x to 21.6x.
Shared on16 Apr 25Fair value Increased 4.35%
AnalystConsensusTarget has decreased revenue growth from 8.0% to 7.2% and decreased shares outstanding growth rate from -0.0% to -0.0%.
Shared on09 Apr 25Fair value Increased 22%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25Fair value Decreased 0.39%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on10 Mar 25Fair value Increased 14%
AnalystConsensusTarget has decreased revenue growth from 9.0% to 8.1%.